Annual Secretarial Compliance Report for the financial year ended 31.03.2025.
BALPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bal Pharma has filed its Annual Secretarial Compliance Report for FY2024-25, certified by Practising Company Secretary Parameshwar G Bhat, covering compliance with SEBI regulations, LODR, Insider Trading, and related party transaction rules. The report confirms compliance across most areas including secretarial standards, policies, website disclosures, director qualifications, insider trading, and performance evaluations. One minor non-compliance was noted: a one-day delay in filing related party transaction disclosures (Regulation 23(9)) with both NSE and BSE, for which the company paid a Rs. 5,000 fine to each exchange. NSE had issued a notice dated 28 June 2024 for this delay. No actions were taken by SEBI against the company, and there were no changes in statutory auditors during the year.
For shareholders, this is largely a routine compliance filing with no material red flags. The only blemish is a minor one-day delay in RPT disclosure resulting in a small fine of Rs. 10,000 total (Rs. 5,000 each to NSE and BSE), which is negligible and unlikely to affect the stock price.